The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission has updated the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Updates include those to reflect new data and publications and to incorporate gender-inclusive language.

The following sections have been updated:

• Introduction
• Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure
• Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods
• Reproductive Options When One or Both Partners Have HIV
• Initial Evaluation and Continued Monitoring of HIV During Pregnancy
• Antiretroviral Therapy for People with HIV Who Are Trying to Conceive
• Pregnant People with HIV Who Have Never Received Antiretroviral Drugs (Antiretroviral-Naive)
• Pregnant People Who Have Not Achieved Viral Suppression on Antiretroviral Therapy
• Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs in Pregnant People and Nonpregnant People Who Are Trying to Conceive
• HIV-2 Infection and Pregnancy
• Early (Acute and Recent) HIV Infection
• Initial Postnatal Management of the Neonate Exposed to HIV
• Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy

For a list of recent updates, please see What's New in the Guidelines. To view or download the guidelines, go to the Perinatal HIV Clinical Guidelines section of Clinicalinfo’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.

In addition to these updates, the shared sections with the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—Diagnosis of HIV Infection in Infants and Children, Infant Feeding for Individuals with HIV in the United States, and Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection—are being revised. It is anticipated these sections will be published in April 2024.

Clinicalinfo welcomes your feedback on the latest revisions to the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Please send your comments with the subject line “Perinatal HIV Clinical Guidelines” to HIVinfo@NIH.gov by February 21, 2024.